Product Details

Verified Reactivity

Human, Cynomolgus, Rhesus

Reported Reactivity

Chimpanzee

Antibody Type

Monoclonal

Host Species

Mouse

Immunogen

Human peripheral T cells

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Preparation

The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Excitation Laser

Red Laser (633 nm)

Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding.　Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.⁹

Application References

(PubMed link indicates BioLegend citation)

1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.

Product Citations

1. Soday L, et al. 2021. Frontiers in Immunology. 12:600056. PubMed
2. Carre C, et al. 2021. iScience. 24:102970. PubMed
3. Wang T, et al. 2022. Front Immunol. 13:954121. PubMed
4. Uhlenbrock F, et al. 2014. J Immunol. 193:1654. PubMed
5. Claiborne DT, et al. 2019. PLoS Pathog. 15:e1007981. PubMed
6. Mete B, et al. 2022. Life Sci Alliance. 5:. PubMed
7. Azizi E et al. 2018. Cell. 174(5):1293-1308 e36. PubMed
8. Want MY, et al. 2019. Oncoimmunology. 8:e1586042. PubMed
9. Sun J, et al. 2018. Scand J Immunol. 88:e12674. PubMed
10. Ahmed R et al. 2019. Cell. 177(6):1583-1599 . PubMed
11. Saadati S, et al. 2020. Avicenna J Med Biotechnol. 0.591666667. PubMed
12. Zhu ZY, et al. 2022. Front Immunol. 12:781087. PubMed
13. Dushyanthen S, et al. 2017. Nat Commun. 10.1038/s41467-017-00728-9. PubMed
14. Wang Z, et al. 2021. Cell Mol Immunol. 18:2188. PubMed
15. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
16. Acerbi E, et al. 2016. Sci Rep. 6:23128. PubMed
17. Altman K 2006. J Immunol . 177:1721. PubMed
18. Li N, et al. 2021. STAR Protoc. 2:100942. PubMed
19. Bellini N, et al. 2022. iScience. 25:105234. PubMed
20. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
21. Narsale A, Moya R, Robertson H 2016. Data Brief. 8: 1348-51. PubMed
22. Sugita S, et al. 2016. Stem Cell Reports. 7:619-634. PubMed
23. Arif S, et al. 2020. Diabetologia. 63(6):1186-1198.. PubMed
24. Alsaleh G, et al. 2020. Elife. 9: . PubMed
25. Jiang H, et al. 2021. Oncoimmunology. 10:1943180. PubMed
26. Wang A, et al. 2020. Front Immunol. 1.213194444. PubMed
27. Zhang J, et al. 2022. Nature. 609:369. PubMed
28. Johnson A, et al. 2016. mSphere. 1: e00288-16. PubMed
29. Bigler M, et al. 2015. PLoS One. 10: 0145635. PubMed
30. Berezhnoy A, et al. 2020. Cell Rep Med. 1:100163. PubMed
31. Jafari M, et al. 2014. J Virol. 88:5062. PubMed
32. Kim K, et al. 2019. Nat Microbiol. 1.586111111. PubMed
33. Frencher J, et al. 2014. J Leukoc Biol. 96:957. PubMed
34. Li N, et al. 2020. Oncoimmunology. 9:1824643. PubMed
35. Li N, et al. 2021. Cell Rep Med. 2:100297. PubMed
36. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
37. Bossini-Castillo L, et al. 2022. Cell Genom. 2:None. PubMed
38. Dupont L, et al. 2021. Cell Host Microbe. 29(5):792-805.e6. PubMed
39. Mishra A, et al. 2021. Cell. 184(13):3394-3409.e20. PubMed
40. Cirelli KM et al. 2019. Cell. 177(5):1153-1171 . PubMed
41. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
42. Ledderose C, et al. 2021. J Leukoc Biol. 109:497. PubMed
43. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
44. Su Y, et al. 2020. Cell. 1479:183. PubMed
45. Mujib S, et al. 2017. JCI Insight. 2:e93687. PubMed
46. Reyes M, et al. 2021. Sci Transl Med. 13:. PubMed
47. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
48. Siedlik J, et al. 2017. J Immunol Methods. 10.1016/j.jim.2017.03.017. PubMed
49. Sashihara J, et al. 2011. PLoS One. 6:e1002308. PubMed
50. Okutani Y, et al. 2022. Tissue Eng Part A. 28:94. PubMed
51. Dotson A, et al. 2013. Clin Immunol. 148:149. PubMed
52. Kang HM, et al. 2018. Nat Biotechnol. 36:89. PubMed

RRID

AB_571944 (BioLegend Cat. No. 317415) AB_571945 (BioLegend Cat. No. 317416)